MYL12A

Across TCGA pan-cancer cohorts, MYL12A mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MYL12A data layer compared with 24 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MYL12A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MYL12A expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC and LSCC are the cancer types where MYL12A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.919	0.614	.009	13	view →
LSCC	DFS	Quartile	II,III,IV	0.705	1.000	.009	8	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MYL12A–CCRCC (DFS)

Open the CCRCC breakdown →